BioEngine Was Ranked On 2023 Future Healthcare VB100 List

May 08, 2023

Leave a message

On May 5-7, 2023, the 7th “Future Healthcare VB100”, organized by VB100, VBData and VCBeat Research and supported by Shanghai Zhangjiang Group, was grandly held in Shanghai Zhangjiang Science Hall. On the evening of May 6, the "2023 Future Healthcare VB100 list” was officially announced. As an advocate and pioneer of China serum-free culture media, BioEngine was ranked in the "Top 100 Medical Commerce and Supply Chain Service Companies" by virtue of its outstanding research and development platform, and production and supply capacity of cell culture media.

“Top 100 Medical Commerce and Supply Chain Service Companies” is the first domestic innovative healthcare list for non-listed companies launched by VB100, VBData and VCBeat Research. It aims to select Chinese innovative healthcare players that truly represent the future of healthcare, discover the core strengths of China's future healthcare industry, and promote the process of innovation and transformation the healthcare industry.

 

news-500-1

news-500-1

news-500-1

Send Inquiry

Provide high quality culture media for research institutions, biopharmaceutical companies and clinical trial institutions, etc.

I agree to receive other communications from BioEngine which may contain technical or marketing information from this organization. You can unsubscribe from these communications at any time.
By submitting this form, you are agreeing to the terms and conditions of our Privacy Policy

Professional Cell Culture Solutions for Biopharmaceutical Development

Our expert scientific team delivers end-to-end cell culture services to support your biopharmaceutical production needs. We provide comprehensive solutions including:
- Process development & optimization
- Customized medium formulation design
- Scalable medium processing & GMP manufacturing

For technical inquiries or service requests, please submit your message through our [Quick Message] portal. Our specialists will respond within 24 business hours.

For urgent matters, please contact +86 137 5514 6322 directly